Parker Institute for Cancer Immunotherapy
Natalie Greco, PhD, serves as Director of Intellectual Property and Licensing on the legal team at PICI. Greco partners with the innovation offices at PICI Member Research Institutions to evaluate and develop new PICI inventions, manage patent prosecution, market PICI technologies, and eventually license the intellectual property to industry partners.
Greco’s interests in research, innovation, and disease prevention inspire her focus on advancing biomedical breakthroughs from bench to market through effective intellectual property management. Throughout her career, Greco has worked closely with researchers to develop and protect their inventions. She has fostered relationships with VCs and companies interested in licensing a variety of biomedical innovations, including therapeutics, research tools, software, and vaccine candidates.
Most recently, Greco worked as a licensing officer in the Innovation Ventures office at the University of California, San Francisco. At UCSF, she managed an active portfolio of cancer immunotherapy technologies, including intellectual property developed by UCSF PICI Member Researchers. Previously, Greco was a Technology Transfer and Patent Specialist in the National Institutes for Allergy and Infectious Diseases at the NIH, where she implemented new marketing strategies for technologies available for licensing and negotiated contracts with industry partners.
She holds a PhD in Cellular and Molecular Pathology from the University of Wisconsin-Madison, where she studied the molecular virology of Hepatitis B Virus. As a post-doc, Greco studied early stages of HIV transmission and efficacy of long-acting drug delivery systems for HIV using imaging-based tools, at Northwestern University in Chicago.
This person is not in any offices
Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.